Posted by Michael Wonder on 27 Jun 2022
FYB201, Formycon's biosimilar for Lucentis (ranibizumab), receives CHMP recommendation from EMA
24 June 2022 - Formycon and its licensing partner Bioeq announce that the CHMP of the EMA today issued a positive opinion for FYB201, a biosimilar to Lucentis.
FYB201 has thus been recommended for approval in the European Union for the treatment of patients with age-related neovascular (wet) macular degeneration and other serious ocular diseases such as diabetic macular oedema, proliferative diabetic retinopathy, macular oedema due to retinal vein occlusion and choroidal neovascularisation.
